Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 3
2011 2
2012 1
2013 13
2014 26
2015 22
2016 34
2017 60
2018 76
2019 106
2020 135
2021 135
2022 135
2023 119
2024 149
2025 163
2026 78

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,094 results

Results by year

Filters applied: . Clear all
Page 1
SGLT2 inhibitors in non-diabetic kidney disease.
Tesař V. Tesař V. Adv Clin Exp Med. 2022 Feb;31(2):105-107. doi: 10.17219/acem/145734. Adv Clin Exp Med. 2022. PMID: 35077036 Free article.
There is an accumulating evidence demonstrating renoprotective and cardioprotective role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in early to advanced diabetic kidney disease. Data from recently published Dapagliflozin and Prevention of Adverse Outcomes …
There is an accumulating evidence demonstrating renoprotective and cardioprotective role of sodium-glucose cotransporter 2 (SGLT2) in …
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
DeFronzo RA, Reeves WB, Awad AS. DeFronzo RA, et al. Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5. Nat Rev Nephrol. 2021. PMID: 33547417 Review.
Unlike other complications of diabetes, the prevalence of diabetic kidney disease has failed to decline over the past 30 years. Hyperglycaemia is the primary aetiological factor responsible for the development of diabetic kidney disease. ...Sodium-glucose co-transpo …
Unlike other complications of diabetes, the prevalence of diabetic kidney disease has failed to decline over the past 30 years. Hyper …
Diabetic Kidney Disease.
Bonner R, Albajrami O, Hudspeth J, Upadhyay A. Bonner R, et al. Prim Care. 2020 Dec;47(4):645-659. doi: 10.1016/j.pop.2020.08.004. Epub 2020 Sep 23. Prim Care. 2020. PMID: 33121634 Review.
Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease in the United States. ...
Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease in the United States. ...
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, Takeda N, Chin-Kanasaki M, Kaneko T, Mayoux E, Mark M, Yanagita M, Ogita H, Araki SI, Maegawa H. Tomita I, et al. Cell Metab. 2020 Sep 1;32(3):404-419.e6. doi: 10.1016/j.cmet.2020.06.020. Epub 2020 Jul 28. Cell Metab. 2020. PMID: 32726607 Free article.
SGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD). ...Furthermore, KBs attenuated mTORC1-associated podocyte damage and proteinuria in diabetic db/db mice. Our findings show that SGLT2 inhibition-associated ren …
SGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD). ...Furthermore, KBs attenuated mT …
Targeting inflammation to treat diabetic kidney disease: the road to 2030.
Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, Navarro-González JF, Ortiz A, Ruiz-Ortega M. Rayego-Mateos S, et al. Kidney Int. 2023 Feb;103(2):282-296. doi: 10.1016/j.kint.2022.10.030. Epub 2022 Dec 5. Kidney Int. 2023. PMID: 36470394 Review.
Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney disease and associated morbidity and mortality. ...
Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney disease and associated morbidity and mortality. …
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefánsson BV, Langkilde AM, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Chertow GM, et al. J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16. J Am Soc Nephrol. 2021. PMID: 34272327 Free PMC article. Clinical Trial.
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in …
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled tria …
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
DeFronzo RA. DeFronzo RA. Diabetes Obes Metab. 2017 Oct;19(10):1353-1362. doi: 10.1111/dom.12982. Epub 2017 Jun 7. Diabetes Obes Metab. 2017. PMID: 28432726 Free PMC article. Review.
The SGLT2 inhibitors (SGLTi) and glucagon-like-1 receptor agonists (GLP-1 RAs) effectively reduce HbA1c, but via very different mechanisms, making them an effective duet for combination therapy. ...
The SGLT2 inhibitors (SGLTi) and glucagon-like-1 receptor agonists (GLP-1 RAs) effectively reduce HbA1c, but via very different mecha …
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Heerspink HJL, et al. Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Kidney Int. 2018. PMID: 29735306 Free article. Review.
However, as with other antihyperglycemic drugs, it could not be known if these salutary effects would translate into improved cardiorenal outcomes. In the EMPA-REG OUTCOME trial, SGLT2 inhibition with empagliflozin reduced the primary outcome of major adverse cardiovascula …
However, as with other antihyperglycemic drugs, it could not be known if these salutary effects would translate into improved cardiorenal ou …
PCK1 Protects against Mitoribosomal Defects in Diabetic Nephropathy in Mouse Models.
Hasegawa K, Sakamaki Y, Tamaki M, Wakino S. Hasegawa K, et al. J Am Soc Nephrol. 2023 Aug 1;34(8):1343-1365. doi: 10.1681/ASN.0000000000000156. Epub 2023 May 18. J Am Soc Nephrol. 2023. PMID: 37199399 Free PMC article.
SIGNIFICANCE STATEMENT: Renal gluconeogenesis plays an important role in the pathogenesis of diabetic nephropathy (DN). Proximal tubular phosphoenolpyruvate carboxykinase1 (PEPCK1) is the rate-limiting enzyme in gluconeogenesis. ...PEPCK consists of two isoforms-PEP …
SIGNIFICANCE STATEMENT: Renal gluconeogenesis plays an important role in the pathogenesis of diabetic nephropathy (DN). Proxim …
The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients.
Sheu JY, Chang LY, Chen JY, Pan HC, Tseng CS, Chueh JS, Wu VC. Sheu JY, et al. Nat Commun. 2024 Nov 20;15(1):10043. doi: 10.1038/s41467-024-54171-8. Nat Commun. 2024. PMID: 39567483 Free PMC article.
Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated efficacy in reducing cardiovascular events and potentially improving kidney function in diabetic patients. This investigation analyzes the TriNetX database to assess the efficacy of SGLT-2i in diabeti …
Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated efficacy in reducing cardiovascular events and potentially improving k …
1,094 results